贝伐珠单抗联合化疗治疗复发性卵巢癌的疗效分析  

Analysis on efficacy of bevacizumab combined with chemotherapy on patients with recurrent ovarian cancer

作　　者：刘宏侠 李万斌[1,2] 韩树斋 LIU Hongxia;LI Wanbin;HAN Shuzhai2(Clinical Medical Collage, Jining Medical University, Jining 272067, Shandong, China;Department of Gynecology, the Affiliated Hospital of Jining Medical University, Jining 272000, Shandong, China)

机构地区：[1]济宁医学院临床医学院,山东济宁272067 [2]济宁医学院附属医院妇科,山东济宁2720000

出　　处：《癌症进展》2018年第14期1790-1793,共4页Oncology Progress

摘　　要：目的探讨贝伐珠单抗联合化疗治疗复发性卵巢癌(OC)的安全性和疗效。方法回顾性分析116例复发性OC患者的临床资料和随访资料,根据治疗方式的不同将患者分为单纯化疗组(n=61)和联合组(n=55),单纯化疗组患者接受紫杉醇+卡铂方案化疗,联合组患者在单纯化疗组的基础上联合应用贝伐珠单抗治疗。比较两组患者的不良反应发生率、近期疗效及生存情况。结果单纯化疗组和联合组患者的各种不良反应发生情况比较,差异均无统计学意义(P﹥0.05);联合组患者的客观有效率(ORR)为47.27%,高于单纯化疗组的24.59%,差异有统计学意义(P﹤0.05)。单纯化疗组患者的中位无进展生存时间(PFS)为4.5个月(95%CI:3.7～5.3个月),明显短于联合组的10.5个月(95%CI:8.2～12.8个月),差异有统计学意义(P﹤0.01);单纯化疗组患者的中位总生存时间(OS)为13.0个月(95%CI:7.7～18.3个月),明显短于联合组的24.0个月(95%CI:17.3～30.7个月),差异有统计学意义(P﹤0.01)。结论贝伐珠单抗联合化疗对复发性OC患者具有良好的疗效,可明显延长患者的中位PFS和OS。Objective To investigate the safety and efficacy of bevacizumab combined with chemotherapy on patients with recurrent ovarian cancer.Method The clinical and follow-up data of116patients with recurrent ovarian cancer were retrospectively analyzed.Patients were divided into chemotherapy group(n=61)and combined group(n=55)according to the treatment regimens.Patients in chemotherapy group were treated with paclitaxel+carboplatin regimen while patients in combined group were treated with bevacizumab combined with paclitaxel/carboplatin regimen chemotherapy.The incidence rate of adverse reactions,short-term efficacy and survival were compared between the two groups.Result There was no significant difference of adverse reaction between two groups(P>0.05).The objective response rate(ORR)of combined group(47.27%)was significantly higher than that of chemotherapy group(24.59%)(P<0.05).The median progression-free survival(PFS)of chemotherapy group was4.5(95%CI:3.7-5.3)months,which was significantly shorter than that of combined group as10.5(95%CI:8.2-12.8)months(P<0.01).The median overall survival(OS)of chemotherapy group was13.0(95%CI:7.7-18.3)months,which was significantly shorter than that of combined group as24.0(95%CI:17.3-30.7)months(P<0.01).Conclusion Bevacizumab combined with chemotherapy is effective on treatment for patients with recurrent ovarian cancer,which can significantly extend the median PFS and OS.

关 键 词：贝伐珠单抗 复发性卵巢癌 疗效 生存情况 

分 类 号：R737.31[医药卫生—肿瘤]